+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cancer Gene Therapy Market Report: Trends, Forecast and Competitive Analysis to 2030

  • PDF Icon

    Report

  • 150 Pages
  • October 2023
  • Region: Global
  • Lucintel
  • ID: 5910121

Cancer Gene Therapy Trends and Forecast

The future of the global cancer gene therapy market looks promising with opportunities in the hospital, biopharmaceutical company, and research institute markets. The global cancer gene therapy market is expected to reach an estimated $7.4 billion by 2030 with a CAGR of 17.4% from 2024 to 2030. The major drivers for this market are increasing demand for gene therapy, advance technological development in cancer treatment and daignosis, and growing incidence of cancer cases.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Cancer Gene Therapy by Segment

The study includes a forecast for the global cancer gene therapy by therapy, indication, end use, and region.

Cancer Gene Therapy Market by Therapy [Shipment Analysis by Value from 2018 to 2030]:

  • Oncolytic Virotherapy
  • Gene Induced Immunotherapy
  • Gene Transfer
  • Others

Cancer Gene Therapy Market by Indication [Shipment Analysis by Value from 2018 to 2030]:

  • Breast Cancer
  • Ovarian Cancer
  • Liver Cancer
  • Pancreatic Cancer
  • Lung Cancer
  • Others

Cancer Gene Therapy Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Biopharmaceutical Companies
  • Research Institutes
  • Others

Cancer Gene Therapy Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Cancer Gene Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cancer gene therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cancer gene therapy companies profiled in this report include-
  • Abeona Therapeutics
  • Asklepios Biopharmaceutical
  • Altor Bioscience
  • Bluebird Bio
  • Biocancell
  • Celgene
  • Elevate Bio
  • Glaxosmithkline
  • Genelux
  • Genvec

Cancer Gene Therapy Market Insights

The publisher forecasts that gene induced immunotherapy will remain the largest sgement over the forecast period due to increasing research & development activities to lower the proliferation of cancer.
Within this market, biopharmaceutical companies will remain the largest segment due to increasing prevelance of cancer and growing adoption of elemental gene therapy solutions by major biopharmaceutical companies for designing cancer treatment regimens.
North America will remain the largest region over the forecast period due to increasing research funding for innovative therapeutics by government entities and the rising demand for novel therapeutics to address the escalating number of cancer cases in the region.

Features of the Global Cancer Gene Therapy Market

  • Market Size Estimates: Cancer gene therapy market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
  • Segmentation Analysis: Cancer gene therapy market size by therapy, indication, end use, and region in terms of value ($B).
  • Regional Analysis: Cancer gene therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different therapies, indications, end uses, and regions for the cancer gene therapy market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cancer gene therapy market.
  • Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

FAQ

Q.1 What is the cancer gene therapy market size?
Answer: The global cancer gene therapy market is expected to reach an estimated $7.4 billion by 2030.

Q.2 What is the growth forecast for cancer gene therapy market?
Answer: The global cancer gene therapy market is expected to grow with a CAGR of 17.4% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the cancer gene therapy market?
Answer: The major drivers for this market are increasing demand for gene therapy, advance technological development in cancer treatment and daignosis, and growing incidence of cancer cases.

Q4. What are the major segments for cancer gene therapy market?
Answer: The future of the cancer gene therapy market looks promising with opportunities in the hospital, biopharmaceutical company, and research institute markets.

Q5. Who are the key cancer gene therapy market companies?

Answer: Some of the key cancer gene therapy companies are as follows:

  • Abeona Therapeutics
  • Asklepios Biopharmaceutical
  • Altor Bioscience
  • Bluebird Bio
  • Biocancell
  • Celgene
  • Elevate Bio
  • Glaxosmithkline
  • Genelux
  • Genvec
Q6. Which cancer gene therapy market segment will be the largest in future?
Answer: The publisher forecasts that gene induced immunotherapy will remain the largest sgement over the forecast period due to increasing research & development activities to lower the proliferation of cancer.

Q7. In cancer gene therapy market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period due to increasing research funding for innovative therapeutics by government entities and the rising demand for novel therapeutics to address the escalating number of cancer cases in the region.

Q.8 Do we receive customization in this report?
Answer: Yes, the publisher provides 10% customization without any additional cost.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the cancer gene therapy market by therapy (oncolytic virotherapy, gene induced immunotherapy, gene transfer, and others), indication (breast cancer, ovarian cancer, liver cancer, pancreatic cancer, lung cancer, and others), end use (hospitals, biopharmaceutical companies, research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
2. Global Cancer Gene Therapy Market : Market Dynamics
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. Market Trends and Forecast Analysis from 2018 to 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Cancer Gene Therapy Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Cancer Gene Therapy Market by Therapy
3.3.1: Oncolytic Virotherapy
3.3.2: Gene Induced Immunotherapy
3.3.3: Gene Transfer
3.3.4: Others
3.4: Global Cancer Gene Therapy Market by Indication
3.4.1: Breast Cancer
3.4.2: Ovarian Cancer
3.4.3: Liver Cancer
3.4.4: Pancreatic Cancer
3.4.5: Lung Cancer
3.4.6: Others
3.5: Global Cancer Gene Therapy Market by End Use
3.5.1: Hospitals
3.5.2: Biopharmaceutical companies
3.5.3: Research Institutes
3.5.4: others
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
4.1: Global Cancer Gene Therapy Market by Region
4.2: North American Cancer Gene Therapy Market
4.2.2: North American Cancer Gene Therapy Market by End Use: Hospitals, Biopharmaceutical companies, Research Institutes, and others
4.3: European Cancer Gene Therapy Market
4.3.1: European Cancer Gene Therapy Market by Therapy: Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer, and Others
4.3.2: European Cancer Gene Therapy Market by End Use: Hospitals, Biopharmaceutical companies, Research Institutes, and others
4.4: APAC Cancer Gene Therapy Market
4.4.1: APAC Cancer Gene Therapy Market by Therapy: Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer, and Others
4.4.2: APAC Cancer Gene Therapy Market by End Use: Hospitals, Biopharmaceutical companies, Research Institutes, and others
4.5: ROW Cancer Gene Therapy Market
4.5.1: ROW Cancer Gene Therapy Market by Therapy: Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer, and Others
4.5.2: ROW Cancer Gene Therapy Market by End Use: Hospitals, Biopharmaceutical companies, Research Institutes, and others
5. Competitor Analysis
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. Growth Opportunities and Strategic Analysis
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Cancer Gene Therapy Market by Therapy
6.1.2: Growth Opportunities for the Global Cancer Gene Therapy Market by Indication
6.1.3: Growth Opportunities for the Global Cancer Gene Therapy Market by End Use
6.1.4: Growth Opportunities for the Global Cancer Gene Therapy Market by Region
6.2: Emerging Trends in the Global Cancer Gene Therapy Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Cancer Gene Therapy Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cancer Gene Therapy Market
6.3.4: Certification and Licensing
7. Company Profiles of Leading Players
7.1: Abeona Therapeutics
7.2: Asklepios BioPharmaceutical
7.3: Altor Bioscience
7.4: Bluebird bio
7.5: BioCancell
7.6: Celgene
7.7: Elevate Bio
7.8: GlaxoSmithKline
7.9: Genelux
7.10: GenVec

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abeona Therapeutics
  • Asklepios Biopharmaceutical
  • Altor Bioscience
  • Bluebird Bio
  • Biocancell
  • Celgene
  • Elevate Bio

Methodology

The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:

  • In-depth interviews of the major players in the market
  • Detailed secondary research from competitors’ financial statements and published data
  • Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
  • A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.

Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.

Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.

 

Loading
LOADING...